Psychedelic drug developer Compass Pathways is preparing to talk to the FDA about filing its psilocybin therapy COMP360 for approval in treatment-resistant depression (TRD), after reporting positive ...
CPC review of 5,000 sales finds Compass at 29.7% to 39.5% share in five metros, raising double-ending and private listing ...
Space Compass and SWISSto12 have executed a procurement contract for the first GEO optical data relay satellite. This agreement represents a milestone toward the realisation of Space Compass’s optical ...
Compass, Zillow, and eXp rolled out coming soon programs with different rules on exclusivity, MLS limits and lead routing.
Investing.com - Stifel reiterated a Buy rating and $12.00 price target on Compass Therapeutics (NASDAQ:CMPX) shares, well above the current stock price of $5.10. The biotech company has delivered a ...
(From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results